From June 3 to 7, 2011, the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) is taking place in Chicago, USA. Roche and Genentech’s investigational and approved cancer medicines are present in approximately 300 abstracts across more than 30 cancer types, demonstrating a leadership role in innovative oncology medicines.
Here you will find the Roche press releases and background materials. For more information about the congress please visit the official congress website.
|June 5 - Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations more...|
|June 4 - Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer more...|
|June 3 - Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse more...|
|May 19 - MetMAb in combination with Tarceva doubled the time people with lung cancer lived without their disease getting worse more...|
|May 18 - Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO more...|
|Non-Small Cell Lung Cancer backgrounder|
|Personalised Healthcare in Oncology|